Vical (VICL)

SUMMARY

BULLS

BEARS

DATA CENTRAL

Day
52 Wk

Biotech Stocks: Drug stocks retract; Vical, Geron, Novavax soar

MarketWatch Jun 30

Drug stocks retract in afternoon trading while shares of Vical Inc. soar on news that animal studies have shown its experimental H1N1 flu vaccine to be highly effective.

Drug stocks inch up; Vical soars on H1N1 update

MarketWatch Jun 30

Vical (VICL) NewsBite - VICL Could Be On The Move

Market Intelligence Center Jun 30

Vical (VICL) was covered in a Bloomberg Video Report today and the stock is now at $2.61, up $0.41 (18.64%) on volume of 4,927,858 shares traded. To see the video report go to http://www.marketintelligencecenter.com/VideoNews . Over the last 52...

Vical says swine flu vaccine works in mice

MarketWatch Jun 30

Vical Inc. said its vaccine against A/H1N1 pandemic influenza, or swine flu, produced robust immune responses well above the accepted protection threshold in 100% of vaccinated mice and rabbits after a standard two-dose vaccine regimen. In...

Vical (VICL) Said Its H1N1 Vaccine Shows 100% Response In Mice and Rabbits

StreetInsider.com Jun 30

Vical (VICL) Receives $1.5M Milestone Payment from Merck (MRK)

StreetInsider.com Jun 22

Visit StreetInsider.com at http://www.streetinsider.com/Corporate+News/Vical+%28VICL%29+Receives+%241.5M+Milestone+Payment+from+Merck+%28MRK%29/4745052.html for the full story.

Vical (VICL) Advances RapidResponse DNA Vaccine Platform Under $6 Million Grant From NIH

StreetInsider.com Jun 18

Visit StreetInsider.com at http://www.streetinsider.com/Corporate+News/Vical+%28VICL%29+Advances+RapidResponse+DNA+Vaccine+Platform+Under+%246+Million+Grant+From+NIH/4739860.html for the full story.

Vical initiated with "overweight"

newratings.com Jun 15

NEW YORK, June 12 (newratings.com) - Analysts at Thomas Weisel initiate coverage of Vical (ticker: VICL) with an "overweight" rating. The target price is set to $5. [more]

Vical (VICL) Issued Patent for Universal Influenza Vaccine Approach

StreetInsider.com Jun 3

Visit StreetInsider.com at http://www.streetinsider.com/FDA/Vical+%28VICL%29+Issued+Patent+for+Universal+Influenza+Vaccine+Approach/4703257.html for the full story.

Vical raises $20M for vaccine programs

FierceBiotech May 27

With its researchers preparing to start human testing on an A/H1N1 vaccine, San Diego-based Vical said that Special Situations Fund had agreed to invest $4.6 million in the company, adding to the $15.4 million that the company raised last week...

Vical raises $15.4M in RDO

FierceBiotech May 22

Vaccine maker Vical announced today that it will raise $14.6 million in a registered direct offering. Federated Kaufmann Fund and another unnamed investor will purchase approximately $15.4 million of securities. Vical expects to receive net...

Biotech Stocks: Drug stocks drop with broader market; Vical soars

MarketWatch May 21

Drug stocks followed the broader market lower into the red as investors fret over whether Standard & Poor’s might take action on the U.S. government's debt rating.

Drug stocks follow market lower; Vical rallies

MarketWatch May 21

Suggest other news sources for this topic


	Suggest a News Source Topic Top news source/blog that we're missing Why do you recommend this news source? Close Thanks for your suggestion!

The article on this company has not been written yet. If you're the first person to write this article, it's a sure thing that you'll be credited as a Top Contributor. For tips on getting started, check out the sample article.

You may also be interested in articles related to Vical (VICL):

Antigenics (AGEN)

[edit] References

Retrieved from "http://www.wikinvest.com/stock/Vical_(VICL)"

Categories: Pharma & Healthcare | Biotechnology

Worried about pump and dump?

We review changes
for stock spam

» read more

Want to make Wikinvest better?

We need your help,
contribute today

» learn how

Do you write software?

We are recruiting
the best engineers

» view jobs

Like Wikinvest?

Spread the word —
Tell your friends!

» spread the word

Wikinvest © 2006, 2007, 2008, 2009. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.